ProCE Banner Activity

Expert Answers to Healthcare Professional Questions on Caring for Patients With Lymphomas During the COVID-19 Pandemic

PDF
In this downloadable PDF resource, multidisciplinary experts answer healthcare professionals’ questions on COVID-19 vaccination and prophylaxis, modifying cancer treatment, and managing adverse events in patients with lymphomas during the COVID-19 pandemic.

Released: November 18, 2021

Expiration: November 17, 2022

No longer available for credit.

Share

Faculty

John N. Allan

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Sandra E. Kurtin

Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pharmacyclics AbbVie Company Janssen Biotech admin Janssen Sci

Faculty Disclosure

Primary Author

John N. Allan, MD

Associate Professor of Clinical Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

John Allan, MD, has disclosed that he has received consulting fees from AbbVie, ADC Therapeutics, BeiGene, Epizyme, Genentech, Janssen, Pharmacyclics, and TG Therapeutics; funds for research support from Genentech, Janssen, and TG Therapeutics; and fees for non-CME/CE services from AbbVie, BeiGene, Janssen, and Pharmacyclics.

Sandra E. Kurtin, PhD, ANP-C, AOCN

Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

Sandra E. Kurtin, PhD, ANP-C, AOCN, has disclosed that she has received consulting fees from AbbVie, Amgen, Bristol-Myers Squibb, Epizyme, Incyte, and Pharmacyclics.